Predictions
Hypoport SE
Start price
Target price
Perf. (%)
€78.45
23.09.22
23.09.22
-
23.10.22
23.10.22
13.58%
24.10.22
24.10.22
Risky Investment
Intra-Cellular Therapies Inc.
Start price
Target price
Perf. (%)
€44.49
23.09.22
23.09.22
€80.00
31.07.25
31.07.25
28.12%
05.05.23
05.05.23
Could be very worthwhile Investment >20% year
Pierre & Vacances S.A.
Start price
Target price
Perf. (%)
€0.80
23.09.22
23.09.22
€1.20
23.09.23
23.09.23
60.50%
24.09.23
24.09.23
Could be worthwhile Investment >10% per year
SPI Energy Co Ltd ADR
Start price
Target price
Perf. (%)
€1.87
22.09.22
22.09.22
-
22.09.23
22.09.23
-29.50%
01.10.22
01.10.22
Risky Investment
Mag Silver Corp.
Start price
Target price
Perf. (%)
€13.06
21.09.22
21.09.22
-
21.10.26
21.10.26
-36.42%
11.03.24
11.03.24
Could be worthwhile Investment >10% per year
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€15.08
21.09.22
21.09.22
-
21.09.23
21.09.23
-4.44%
01.10.22
01.10.22
Risky Investment
flatexDEGIRO AG
Start price
Target price
Perf. (%)
€9.18
20.09.22
20.09.22
€6.00
20.09.23
20.09.23
0.33%
01.10.22
01.10.22
Could be worthwhile Investment >10% per year
Good culture
Below average Management
Little innovation
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.05
20.09.22
20.09.22
€1.80
20.09.23
20.09.23
36.59%
19.11.22
19.11.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Inovio Pharma
Start price
Target price
Perf. (%)
€1.88
20.09.22
20.09.22
€1.60
20.09.23
20.09.23
-7.46%
03.10.22
03.10.22
Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Bed Bath & Beyond Inc.
Start price
Target price
Perf. (%)
€7.75
20.09.22
20.09.22
€3.00
20.09.23
20.09.23
-52.24%
11.01.23
11.01.23
Revenue growth >5% per year expected
Higher EBIT margin than peer group
Very low/no dividend yield expected
very negative Cash Flow expected
Clovis Oncology Inc.
Start price
Target price
Perf. (%)
€1.17
20.09.22
20.09.22
-
20.09.23
20.09.23
-15.38%
15.10.22
15.10.22
Risky Investment
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€16.65
20.09.22
20.09.22
€32.00
31.01.23
31.01.23
-17.72%
30.09.22
30.09.22
Could be very worthwhile Investment >20% year
Minerva Neurosciences Inc.
Start price
Target price
Perf. (%)
€8.64
19.09.22
19.09.22
€17.00
19.09.23
19.09.23
-34.41%
17.10.22
17.10.22
Could be very worthwhile Investment >20% year
Forte Biosciences Inc.
Start price
Target price
Perf. (%)
€1.21
19.09.22
19.09.22
-
19.09.23
19.09.23
-12.19%
01.10.22
01.10.22
Capable Management
Could be very worthwhile Investment >20% year
Few uniques
Vitesco Technologies Group AG
Start price
Target price
Perf. (%)
€49.82
19.09.22
19.09.22
€60.00
19.09.23
19.09.23
21.94%
30.05.23
30.05.23
Vivani Medical Inc.
Start price
Target price
Perf. (%)
€2.81
19.09.22
19.09.22
-
19.09.23
19.09.23
-67.84%
24.04.23
24.04.23
Probably not worthwhile Investment
Marathon Digital Holdings
Start price
Target price
Perf. (%)
€10.50
19.09.22
19.09.22
-
19.09.23
19.09.23
-8.86%
08.11.22
08.11.22
Could be worthwhile Investment >10% per year
Very high cyclical dependencies
Athersys Inc.
Start price
Target price
Perf. (%)
€1.87
19.09.22
19.09.22
€3.80
19.09.23
19.09.23
0.19%
17.10.22
17.10.22
Could be very worthwhile Investment >20% year
Hipay Group S.A.
Start price
Target price
Perf. (%)
€6.04
19.09.22
19.09.22
-
19.09.23
19.09.23
39.07%
10.08.23
10.08.23
Probably not worthwhile Investment
Intercept Pharmaceuticals
Start price
Target price
Perf. (%)
€17.43
18.09.22
18.09.22
-
18.09.23
18.09.23
-17.30%
01.10.22
01.10.22
Risky Investment
Hipay Group S.A.
Start price
Target price
Perf. (%)
€6.04
17.09.22
17.09.22
€4.00
17.09.23
17.09.23
-30.88%
01.10.22
01.10.22
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Business model of the past or high risk
Applied Optoelectronics Inc.
Start price
Target price
Perf. (%)
€3.73
17.09.22
17.09.22
€1.00
17.09.23
17.09.23
-26.73%
01.10.22
01.10.22
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Bad rating
Below average Management